CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Trey Yon who wrote (588)	7/26/2000 9:15:41 AM
From: Russian Bear	Read Replies (2) of 666

biz.yahoo.com Unless my understanding of the patent language is severely flawed, this is very, very big. It would seem to put IDPH and Zevalin in a precarious position, in a way that the previous patent did not do. <<Coulter Pharmaceutical and SmithKline Beecham Expand Proprietary Position With Second U.S. Patent Grant This Year SOUTH SAN FRANCISCO, Calif. & PHILADELPHIA--(BW HealthWire)--July 26, 2000--Coulter Pharmaceutical (Nasdaq:CLTR - news) and SmithKline Beecham (NYSE:SBH - news) today announced that the U.S. Patent and Trademark Office has issued another patent relating to CD20 antibody therapy for the treatment of lymphoma. The newest patent, number 6090365, is a method-of-use patent relating to the administration of antibodies that bind to the CD20 antigen...>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next